Old API Wind-down Ltd. Stock

Stocks

ARLZQ

CA03852X1006

Pharmaceuticals

OTC Markets Traded
Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Old API Wind-down Ltd. -.--% -
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Old API Wind-down Ltd.

Market Cap 87.35K 75.45K 69.52K 65.08K 122K 8.3M 124K 821K 320K 4.04M 328K 321K 13.99M P/E Ratio 2016
-2.53x
P/E Ratio 2017 -0.75x
Enterprise Value 246M 212M 196M 183M 343M 23.36B 348M 2.31B 900M 11.37B 922M 903M 39.37B EV / Sales 2016
9.18x
EV / Sales 2017 3.22x
Free-Float
100%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-2.28%+0.55%+40.10%+155.47% 1,035B
+0.87%+3.42%+53.66%+50.55% 574B
+1.13%-0.11%+17.97%+64.81% 397B
+0.58%+0.77%+21.19%+15.95% 324B
-0.85%-2.86%+22.05%+13.80% 281B
+0.44%+3.48%+24.48%+34.39% 278B
+1.66%+5.61%-44.67%-47.49% 193B
+0.09%+1.27%+19.09%+62.88% 191B
-0.30%-2.77%+12.07%+61.29% 156B
Average +0.11%+1.51%+18.44%+45.74% 342.99B
Weighted average by Cap. -0.31%+2.39%+28.05%+71.93%

Financials

2016 2017
Net sales 54.27M 46.87M 43.19M 40.43M 75.77M 5.16B 76.94M 510M 199M 2.51B 204M 199M 8.69B 106M 91.51M 84.32M 78.93M 148M 10.07B 150M 996M 388M 4.9B 398M 389M 16.97B
Net income -103M -88.94M -81.96M -76.72M -144M -9.79B -146M -968M -377M -4.76B -386M -378M -16.5B -125M -108M -99.65M -93.28M -175M -11.9B -178M -1.18B -459M -5.79B -470M -460M -20.06B
Net Debt 209M 181M 167M 156M 292M 19.91B 297M 1.97B 768M 9.69B 786M 770M 33.56B 246M 212M 196M 183M 343M 23.35B 348M 2.31B 900M 11.37B 922M 902M 39.35B
Logo Old API Wind-down Ltd.
Old API Wind-Down Ltd, formerly Aralez Pharmaceuticals Inc., is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
Employees
-
  1. Stock Market
  2. Stocks
  3. ARLZQ Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!